# Multiple Sclerosis Research Studies

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/multiple-sclerosis-research-studies/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, pathogenesis, and treatment of multiple sclerosis (MS) and related disorders such as neuromyelitis optica. It covers topics such as the diagnostic criteria for MS, genetic risk factors, immune mechanisms involved in MS, cognitive impairment, axonal injury, and the autoimmune pathology underlying the disease. The papers also discuss the use of various therapies and their effects on MS patients. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10137 |
| Works | 468 |

## Topic papers all

Showing 15 of 468.

- [Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016](https://scholariq.org/papers/global-regional-and-national-burden-of-neurological-disorders-1990-2016-a/)
- [International consensus diagnostic criteria for neuromyelitis optica spectrum disorders](https://scholariq.org/papers/international-consensus-diagnostic-criteria-for-neuromyelitis-optica-spectrum/)
- [Defining the clinical course of multiple sclerosis](https://scholariq.org/papers/defining-the-clinical-course-of-multiple-sclerosis/)
- [Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis](https://scholariq.org/papers/genetic-risk-and-a-primary-role-for-cell-mediated-immune-mechanisms-in-multiple/)
- [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/)
- [Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-belimumab-in-patients-with-active-systemic-lupus/)
- [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](https://scholariq.org/papers/a-phase-iii-randomized-placebo-controlled-study-of-belimumab-a-monoclonal/)
- [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology-2/)
- [Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis](https://scholariq.org/papers/analysis-of-immune-related-loci-identifies-48-new-susceptibility-variants-for/)
- [Trial of Anifrolumab in Active Systemic Lupus Erythematosus](https://scholariq.org/papers/trial-of-anifrolumab-in-active-systemic-lupus-erythematosus/)
- [Development of a multiple sclerosis functional composite as a clinical trial outcome measure](https://scholariq.org/papers/development-of-a-multiple-sclerosis-functional-composite-as-a-clinical-trial/)
- [Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria](https://scholariq.org/papers/diagnosis-of-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/)
- [The prevalence of MS in the United States](https://scholariq.org/papers/the-prevalence-of-ms-in-the-united-states/)
- [Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide](https://scholariq.org/papers/immunosuppressive-therapy-in-lupus-nephritis-the-euro-lupus-nephritis-trial-a/)
- [Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis](https://scholariq.org/papers/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis/)

## Topic primary papers

Showing 15 of 289.

- [International consensus diagnostic criteria for neuromyelitis optica spectrum disorders](https://scholariq.org/papers/international-consensus-diagnostic-criteria-for-neuromyelitis-optica-spectrum/)
- [Defining the clinical course of multiple sclerosis](https://scholariq.org/papers/defining-the-clinical-course-of-multiple-sclerosis/)
- [Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis](https://scholariq.org/papers/analysis-of-immune-related-loci-identifies-48-new-susceptibility-variants-for/)
- [Development of a multiple sclerosis functional composite as a clinical trial outcome measure](https://scholariq.org/papers/development-of-a-multiple-sclerosis-functional-composite-as-a-clinical-trial/)
- [Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria](https://scholariq.org/papers/diagnosis-of-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/)
- [The prevalence of MS in the United States](https://scholariq.org/papers/the-prevalence-of-ms-in-the-united-states/)
- [The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment](https://scholariq.org/papers/the-multiple-sclerosis-functional-composite-measure-msfc-an-integrated-approach/)
- [Multiple Sclerosis Severity Score](https://scholariq.org/papers/multiple-sclerosis-severity-score/)
- [Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study](https://scholariq.org/papers/siponimod-versus-placebo-in-secondary-progressive-multiple-sclerosis-expand-a/)
- [MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome](https://scholariq.org/papers/mog-igg-in-nmo-and-related-disorders-a-multicenter-study-of-50-patients-part-2/)
- [A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease](https://scholariq.org/papers/a-randomized-trial-of-plasma-exchange-in-acute-central-nervous-system/)
- [A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis](https://scholariq.org/papers/a-longitudinal-study-of-abnormalities-on-mri-and-disability-from-multiple/)
- [Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders](https://scholariq.org/papers/distinction-between-mog-antibody-positive-and-aqp4-antibody-positive-nmo/)
- [Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients](https://scholariq.org/papers/contrasting-disease-patterns-in-seropositive-and-seronegative-neuromyelitis/)
- [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing](https://scholariq.org/papers/mog-encephalomyelitis-international-recommendations-on-diagnosis-and-antibody/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.